(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...

Dr Reddy's Laboratories share price plunged 6.66 per cent at Rs 1,203.50 per share on the NSE in Friday's intraday deals ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Dr. Reddy's shares are the top losers on the Nifty 50 index today. Out of the 40 analysts that have coverage on Dr. Reddy's, ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...